Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. STRO
stocks logo

STRO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
8.27M
-44.18%
-0.435
-47.61%
8.86M
-49.06%
-0.408
-55.13%
8.90M
-86.04%
-0.380
+171.43%
Estimates Revision
The market is revising Upward the revenue expectations for Sutro Biopharma, Inc. (STRO) for FY2025, with the revenue forecasts being adjusted by 0.21% over the past three months. During the same period, the stock price has changed by -11.51%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.21%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+15.27%
In Past 3 Month
Stock Price
Go Down
down Image
-11.51%
In Past 3 Month
Wall Street analysts forecast STRO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for STRO is 2.20 USD with a low forecast of 0.80 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast STRO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for STRO is 2.20 USD with a low forecast of 0.80 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 9.380
sliders
Low
0.80
Averages
2.20
High
4.00
Current: 9.380
sliders
Low
0.80
Averages
2.20
High
4.00
Jefferies
Buy
downgrade
$7 -> $4
2025-09-09
Reason
Jefferies
Price Target
$7 -> $4
2025-09-09
downgrade
Buy
Reason
Jefferies lowered the firm's price target on Sutro Biopharma to $4 from $7 and keeps a Buy rating on the shares. After having caught up with management, the firm updated its operating expense estimates based on early pipeline expectations, the analyst tells investors.
Wells Fargo
Equal Weight
downgrade
$4 -> $3
2025-08-12
Reason
Wells Fargo
Price Target
$4 -> $3
2025-08-12
downgrade
Equal Weight
Reason
Wells Fargo lowered the firm's price target on Sutro Biopharma to $3 from $4 and keeps an Equal Weight rating on the shares. The firm remains on the sidelines given the early nature of Sutro's clinical pipeline as management works to get its multiple ADC programs into the clinic. Shares are likely to remain range bound, Wells adds.
Piper Sandler
Neutral -> Overweight
upgrade
$2
2025-06-17
Reason
Piper Sandler
Price Target
$2
2025-06-17
upgrade
Neutral -> Overweight
Reason
Piper Sandler last night upgraded Sutro Biopharma to Overweight from Neutral with an unchanged price target of $2. The company plans to file three new drug applications on next-generation antibody-drug conjugates over the next three years, the analyst tells investors in a research note. The firm says Sutro ended Q1 with cash of $249M to fund operations into 2027 and currently trades at a negative $181M enterprise value. Piper sees an attractive valuation at current share levels.
Piper Sandler
Neutral -> Overweight
upgrade
$2
2025-06-15
Reason
Piper Sandler
Price Target
$2
2025-06-15
upgrade
Neutral -> Overweight
Reason
Piper Sandler upgraded Sutro Biopharma to Overweight from Neutral with an unchanged price target of $2.
BofA
Underperform
downgrade
$1
2025-05-19
Reason
BofA
Price Target
$1
2025-05-19
downgrade
Underperform
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
to
Hold
Downgrades
$12 → $2
2025-03-17
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$12 → $2
2025-03-17
Downgrades
Strong Buy
to
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Sutro Biopharma Inc (STRO.O) is -0.63, compared to its 5-year average forward P/E of -2.99. For a more detailed relative valuation and DCF analysis to assess Sutro Biopharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.99
Current PE
-0.63
Overvalued PE
0.09
Undervalued PE
-6.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.56
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.57
Undervalued EV/EBITDA
-2.69

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
8.36
Current PS
0.00
Overvalued PS
15.75
Undervalued PS
0.97
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

STRO News & Events

Events Timeline

(ET)
2025-12-03
08:10:00
Sutro Biopharma Doses First Patients in STRO-004 Phase 1 Trial
select
2025-12-01 (ET)
2025-12-01
08:10:00
Sutro Biopharma Approves 1-for-10 Reverse Stock Split
select
2025-09-29 (ET)
2025-09-29
17:06:57
Sutro Biopharma Reveals Restructuring Plans and 33% Workforce Cut
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03Globenewswire
Sutro Biopharma Initiates Phase 1 Trial of STRO-004, Initial Data Expected Mid-2026
  • Trial Initiation: Sutro Biopharma has successfully dosed the first cohort of patients in its Phase 1 trial for STRO-004 targeting various Tissue Factor (TF) expressing solid tumors, marking a significant milestone in providing new treatment options for cancer patients with limited therapies.
  • Drug Design Advantages: STRO-004 is developed using Sutro's proprietary cell-free platform, engineered for superior stability, potency, and tumor selectivity, aiming to deliver stronger anti-tumor activity compared to existing therapies, thereby addressing urgent treatment needs.
  • Dose Escalation Strategy: The trial's dose-escalation phase includes multiple cohorts, supported by strong tolerability in non-human primates at doses up to 50 mg/kg, with the goal of rapidly identifying a recommended Phase 2 dose and observing early signs of clinical activity to guide further development.
  • Market Potential: Targeting the clinically validated TF antigen expressed across various solid tumors, STRO-004 is expected to open new market opportunities for Sutro in oncology, particularly in treating tumor types resistant to standard therapies.
[object Object]
Preview
2.0
12-01Globenewswire
Sutro Biopharma Approves 1-for-10 Reverse Stock Split to Meet Nasdaq Compliance
  • Reverse Stock Split Decision: Sutro Biopharma's Board has approved a 1-for-10 reverse stock split aimed at regaining compliance with Nasdaq's minimum bid price requirement of $1.00 per share, thereby ensuring continued listing eligibility.
  • Shareholder Meeting Support: The reverse stock split plan was approved at the annual shareholder meeting on June 6, 2025, reflecting shareholder confidence in the company's governance and future development.
  • Share Count Adjustment: Post-split, Sutro's outstanding shares will decrease from approximately 85.2 million to about 8.5 million, impacting all shareholders uniformly while maintaining their percentage ownership interests.
  • Trading Symbol Remains Unchanged: The reverse stock split will take effect on December 3, 2025, with Sutro's stock continuing to trade under the symbol “STRO”, ensuring market recognition and liquidity are not adversely affected.
[object Object]
Preview
2.0
12-01NASDAQ.COM
Sutro Biopharma Implements 1-for-10 Reverse Stock Split

  • Reverse Stock Split Announcement: Sutro Biopharma, Inc. has approved a 1-for-10 reverse stock split of its common stock to comply with Nasdaq's minimum bid price requirement.

  • Impact on Shares: The reverse stock split will reduce the number of shares from approximately 85 million to about 8.5 million and will take effect on December 3, 2023.

  • Trading Details: Post-split, the common stock will continue trading under the symbol STRO, with a new CUSIP number of 869367201.

  • Current Stock Performance: As of pre-market trading, STRO shares were priced at $0.85, reflecting a decline of 7.41% on the Nasdaq.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Sutro Biopharma Inc (STRO) stock price today?

The current price of STRO is 9.38 USD — it has increased 7.82 % in the last trading day.

arrow icon

What is Sutro Biopharma Inc (STRO)'s business?

Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.

arrow icon

What is the price predicton of STRO Stock?

Wall Street analysts forecast STRO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for STRO is 2.20 USD with a low forecast of 0.80 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Sutro Biopharma Inc (STRO)'s revenue for the last quarter?

Sutro Biopharma Inc revenue for the last quarter amounts to 9.69M USD, increased 13.77 % YoY.

arrow icon

What is Sutro Biopharma Inc (STRO)'s earnings per share (EPS) for the last quarter?

Sutro Biopharma Inc. EPS for the last quarter amounts to -0.67 USD, increased 13.56 % YoY.

arrow icon

What changes have occurred in the market's expectations for Sutro Biopharma Inc (STRO)'s fundamentals?

The market is revising Upward the revenue expectations for Sutro Biopharma, Inc. (STRO) for FY2025, with the revenue forecasts being adjusted by 0.21% over the past three months. During the same period, the stock price has changed by -11.51%.
arrow icon

How many employees does Sutro Biopharma Inc (STRO). have?

Sutro Biopharma Inc (STRO) has 310 emplpoyees as of December 05 2025.

arrow icon

What is Sutro Biopharma Inc (STRO) market cap?

Today STRO has the market capitalization of 79.86M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free